Jump to content

Anastasis

Certifiably Surly
  • Posts

    31709
  • Joined

  • Days Won

    8

Everything posted by Anastasis

  1. I don't know where yall are pulling this stuff from, but here is the actual data: https://sda.berkeley.edu/sdaweb/analysis/exec?formid=tbf&sdaprog=tables&dataset=gss24rel1&sec508=false&row=year&column=numwomen(d%3A0)&filters=sex(1)%2Cage(18-29)&weightlist=compwt&rowpct=on&design=complex&confidence=on&cflevel=95&weightedn=on&color=on&ch_type=line&ch_color=yes&ch_width=600&ch_height=400&decpcts=1&decse=1&decdeft=3&decwn=1&decstats=2&csvformat=no&csvfilename=tables.csv
  2. Risk of fatal accident on the bus is like an order of magnitude higher than a shoot shooting when the exposure time is assessed correctly.
  3. School bus driver shortage has been a big issue. Based on the pics no sure how you roll that thing unless maybe your speed is a little high and you understeer. Thankfully sounds like the kids are mostly ok.
  4. That chart is fake y’all.
  5. The data released today are not really compelling from a revenue generating perspective. Rare disease. Positive results, but early read out from 2 patients participating in open label N=12 study. Positive stuff I guess is the stuff press releases are made of. I am not really sure what moves these biotechs.
  6. I like the stock.
  7. I should have bought more TLRY but don't want to jinx it now.
  8. Looks like IBRX reading out a positive study in rare form of non-hodgkin lymphoma today. https://immunitybio.com/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy/
  9. Nice post. TLRY has been good for a +30% win in 24h.
  10. That's been a real smoove buttfucking.
  11. Anastasis

    Fade me how

    on theme...
  12. In Jesse Griffiths I trust on these things.
  13. Oh, and after they killed her they threw stun grenades and assaulted her funeral.
  14. They assassinated an American citizen doing journalism in the WB, lied about it until that was no longer tenable, and we didn’t do shit about it. It’s just amazing.
  15. Sarepta and Laura Loomer. lol.
  16. And then a drop in at the chili parlor. Am I misremembering or was there a crockpot of queso at the end of the bar most of the time. Shits kinda hazy.
  17. Twice, here is an article from 2022 and another more recent. Also the FDA review. would love to hear your critique of the FDA memo, it’s not really my area. https://amp.cnn.com/cnn/2022/04/07/business/cultivated-salmon-wildtype-climate-scn-hnk-spc-intl https://agfundernews.com/fda-clears-wildtypes-cell-cultivated-salmon-for-us-debut https://www.fda.gov/media/186753/download
  18. What is the fascination the billionaires have with artificial protein projects?
  19. That shit sounds totally horrible. Would like to see more info and deep dive than a tweet, but that all sounds crazy.
  20. I don’t think Rfk cares one way or another. People can read your post on this page and then read mine and assess which one they find more relevant and valuable to understanding what is taking place at nih.
  21. This is what’s being referred to clumsily and imprecisely in that clip. Yet to be seen if they can land it. https://www.nih.gov/news-events/news-releases/hhs-nih-launch-next-generation-universal-vaccine-platform-pandemic-prone-viruses Thursday, May 1, 2025 HHS, NIH launch next-generation universal vaccine platform for pandemic-prone viruses Image Colorized transmission electron micrograph of influenza A/H1N1 virus particles. The U.S. Department of Health and Human Services (HHS) and the National Institutes for Health (NIH) today announced the development of the next-generation, universal vaccine platform, Generation Gold Standard, using a beta-propiolactone (BPL)-inactivated, whole-virus platform. This initiative represents a decisive shift toward transparency, effectiveness, and comprehensive preparedness, funding the NIH’s in-house development of universal influenza and coronavirus vaccines, including candidates BPL-1357 and BPL-24910. These vaccines aim to provide broad-spectrum protection against multiple strains of pandemic-prone viruses such as H5N1 avian influenza and coronaviruses including SARS-CoV-2, SARS-CoV-1, and MERS-CoV. “Our commitment is clear: every innovation in vaccine development must be grounded in gold standard science and transparency, and subjected to the highest standards of safety and efficacy testing,” said HHS Secretary Robert F. Kennedy, Jr. The program realigns BARDA’s operations with its statutory mission under the Public Health Service Act—to prepare for all influenza viral threats, not just those currently circulating. “Generation Gold Standard is a paradigm shift,” said NIH Director Dr. Jay Bhattacharya. “It extends vaccine protection beyond strain-specific limits and prepares for flu viral threats – not just today’s, but tomorrow’s as well – using traditional vaccine technology brought into the 21st century.” Generation Gold Standard, developed exclusively by NIH’s National Institute of Allergy and Infectious Diseases (NIAID): Recalibrates America’s pandemic preparedness. Unlike traditional vaccines that target specific strains, BPL-inactivated whole-virus vaccines preserve the virus’s structural integrity while eliminating infectivity. This approach induces robust B and T cell immune responses and offers long-lasting protection across diverse viral families. Moreover, the intranasal formulation of BPL-1357 is currently in Phase Ib and II/III trials and is designed to block virus transmission—an innovation absent from current flu and COVID-19 vaccines. Embodies efficient, transparent, and government-led research. The BPL platform is fully government-owned and NIH-developed. This approach ensures radical transparency, public accountability, and freedom from commercial conflicts of interest. Marks the future of vaccine development. In addition to influenza and coronavirus, the BPL platform is adaptable for future use against respiratory syncytial virus (RSV), metapneumovirus, and parainfluenza. It also offers the unprecedented capability to protect against avian influenza without inducing antigenic drift—a major step forward in proactive pandemic prevention. Clinical trials for universal influenza vaccines are scheduled to begin in 2026, with Food and Drug Administration (FDA) approval targeted for 2029. The intranasal BPL-1357 flu vaccine, currently in advanced trials, is also on track for FDA review by 2029. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
  22. Batshit crazy 10-20% of the time was the other part of that. BTW. Flu shots started shipping last month. I know that some posters were really worried about that this year. Already in some pharmacies. Don't forget to get in early and get your shot before the season gets wound up.
  23. Imagine not even keeping count.
  24. You can disagree with anything you like. Doesn't really change the real world evidence.
×
×
  • Create New...